Moreover, we did not evaluate the anti-leukemic role of targeting CD123 in EP300-ZNF84 positive B-ALL; thus, further research should explore therapeutic potential of CD123-targeted therapies including CAR-engineered T cells, neutralizing antibodies, and IL3RA antibodies coupled to toxins. Here, IL3RA is linked to acute lymphoblastic leukemia.